Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이민종 | - |
dc.date.accessioned | 2021-06-07T16:31:27Z | - |
dc.date.available | 2021-06-07T16:31:27Z | - |
dc.date.issued | 2021 | - |
dc.identifier.issn | 1936-0533 | - |
dc.identifier.other | OAK-29365 | - |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/257625 | - |
dc.description.abstract | Background/Aim: We investigated the effect of non-selective β-blockers (NSBB) in real-world situations and whether low-dose NSBB is beneficial compared to maximally tolerated doses. Methods: We performed a retrospective study of 740 patients with cirrhosis requiring prophylactic treatment of esophageal varices: 473 primary prophylaxis (PP: NSBB = 349, non-NSBB = 124) and 267 secondary prophylaxis (SP: NSBB = 200, non-NSBB = 67). The NSBB group was divided into low-dose (≤ 80 mg/day) and high-dose (> 80 mg/day). Results: In the PP group, NSBB treatment reduced mortality and showed the most pronounced effect in patients with moderate/severe ascites (hazard ratio [HR], 0.46; p < 0.01), HVPG ≥ 16 mmHg (HR, 0.53; p = 0.04), or CTP class B/C (HR, 0.46; p < 0.01) but not in those with no/mild ascites, HVPG < 16 mmHg, or CTP class A. Low-dose NSBB group showed a significant reduction in mortality compared with non-NSBB (moderate/severe ascites: HR, 0.61; p = 0.02 and CTP class B/C: HR, 0.41; p < 0.01) and the effect size was stronger than the high-dose NSBB. NSBB was associated with a reduced risk of infection (HR, 0.36; p = 0.01). In the SP group, NSBB prolonged survival in patients with moderate/severe ascites (HR, 0.56; p = 0.02), HVPG ≥ 16 mmHg (HR, 0.42; p < 0.01), or CTP class B/C (HR, 0.52; p < 0.01). Low-dose NSBB was more beneficial with 56% risk reduction (p < 0.01) of mortality compared with 33% risk reduction in the high-dose NSBB (p = 0.05). Conclusion: NSBB therapy was associated with longer survival in PP and SP groups who had an advanced stage of cirrhosis. Moreover, low-dose NSBB exhibited a better benefit than a standard-titrated high-dose NSBB with better tolerability. © 2021, Asian Pacific Association for the Study of the Liver. | - |
dc.description.sponsorship | Kim, M.Y.; Division of Gastroenterology and Hepatology, 20, Ilsan-ro, South Korea; email: drkimmy@yonsei.ac.kr | - |
dc.language | English | - |
dc.publisher | Springer | - |
dc.subject | Ascites | - |
dc.subject | Esophageal varix | - |
dc.subject | Hepatic venous pressure gradient | - |
dc.subject | Liver cirrhosis | - |
dc.subject | Low-dose non-selective β-blockers | - |
dc.subject | Nonselective β-blockers | - |
dc.subject | Portal hypertension | - |
dc.subject | Severity | - |
dc.subject | Survival | - |
dc.subject | Treatment | - |
dc.title | The longitudinal outcomes of applying non-selective beta-blockers in portal hypertension: real-world multicenter study | - |
dc.type | Article | - |
dc.relation.issue | 2 | - |
dc.relation.volume | 15 | - |
dc.relation.index | SCIE | - |
dc.relation.index | SCOPUS | - |
dc.relation.startpage | 424 | - |
dc.relation.lastpage | 436 | - |
dc.relation.journaltitle | Hepatology International | - |
dc.identifier.doi | 10.1007/s12072-021-10160-3 | - |
dc.identifier.wosid | WOS:000640728600001 | - |
dc.identifier.scopusid | 2-s2.0-85104813316 | - |
dc.author.google | Kang S.H. | - |
dc.author.google | Lee M. | - |
dc.author.google | Kim M.Y. | - |
dc.author.google | Lee J.H. | - |
dc.author.google | Jun B.G. | - |
dc.author.google | Kim T.S. | - |
dc.author.google | Choi D.H. | - |
dc.author.google | Suk K.T. | - |
dc.author.google | Kim Y.D. | - |
dc.author.google | Cheon G.J. | - |
dc.author.google | Kim D.J. | - |
dc.author.google | Baik S.K. | - |
dc.contributor.scopusid | 이민종(55917792000) | - |
dc.date.modifydate | 20230310081003 | - |